Disease Landscape and Forecast Insights

Last Updated 11 December 2014 The HIV therapy market is highly dynamic. Over the past ten years, many effective antiretroviral therapies (ARTs) have been introduced, prompting changes in treatment…

Chronic obstructive pulmonary disease (COPD) is a disease encompassing chronic bronchitis and emphysema that generally affects smokers and older patients. Current treatment of COPD is dominated by…

This quarterly report series covers the management of dialysis and mid- to late-stage chronic kidney disease (CKD) patients from the perspective of nephrologists. Emphasis is on anemia management (…

Cervical cancer is reported to be the fourth most common form of cancer in women worldwide, despite the introduction of screening programs and vaccination programs against the virus known to cause…

Psoriasis is a chronic inflammatory skin disorder that, although non-life-threatening, can have a major impact on patients’ quality of life depending on its severity and location on the body. The…

Last Updated 4 December 2014 Unipolar depression—comprising major depressive disorder (MDD), minor depression, and dysthymia—is a highly prevalent psychiatric disorder affecting nearly 85…

Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organ systems, manifesting at various levels of severity, and involving periods of remission and relapse. The…

Last Updated 4 December 2014 The migraine market consists of a multitude of therapies that either acutely treat migraine attacks or serve as prophylactic treatment. Among acute antimigraine…

For the estimated 35 million people in the United States who experience migraines, multiple prescription therapies are available that have proved effective in acutely treating migraine pain and its…

For the estimated 2.1 million people in the United States with rheumatoid arthritis (RA), there are multiple disease modifying anti-rheumatic drugs (DMARDs) available for reducing the signs and…

The symptomology of Parkinson’s disease (PD) is heterogeneous; individual patients experience different combinations of primary motor symptoms, complications of therapy, and/or key nonmotor…

For the estimated 4.6 million people in the United States who suffer from atrial fibrillation (AF), several treatment approaches and a wide range of pharmacological treatment options are available…